Lb Pharmaceuticals (LBRX) Cash from Operations (2024 - 2026)

Lb Pharmaceuticals' Cash from Operations history runs 3 years deep, the most recent figure standing at 23300000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 186.66% year-over-year to 23300000.0 in Q1 2026; TTM through Mar 2026 was 55193000.0, a N/A change from a year earlier, with the FY2025 full-year figure at 35200000.0, up 33.65% from the prior year.
• Cash from Operations fell to 23300000.0 in Q1 2026 per LBRX's latest filing, from 18100000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 5665000.0 in Q4 2024 and bottomed at 23300000.0 in Q1 2026.
• The 3-year median for Cash from Operations is 13114000.0 (2025), against an average of 13798250.0.
• Across the five-year window, Cash from Operations sank 219.51% in 2025 and slumped 186.66% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 5665000.0 in 2024, then sank by 219.51% to 18100000.0 in 2025, then decreased by 28.73% to 23300000.0 in 2026.
• Per Business Quant, the three latest LBRX Cash from Operations figures stand at 23300000.0 (Q1 2026), 18100000.0 (Q4 2025), and 8128000.0 (Q1 2025).